Thomas L Vaughan

List of Publications by Year
in descending order

94 papers	5,599 citations	71102 41 h-index	82547 72 g-index
95 all docs	95 docs citations	95 times ranked	6167 citing authors

#	Article	IF	Citations
1	The impact of low-fat and full-fat dairy foods on symptoms of gastroesophageal reflux disease: an exploratory analysis based on a randomized controlled trial. European Journal of Nutrition, 2022, 61, 2815-2823.	3.9	4
2	A risk variant for Barrettâ€™s esophagus and esophageal adenocarcinoma at chr8p23.1 affects enhancer activity and implicates multiple gene targets. Human Molecular Genetics, 2022, 31, 3975-3986.	2.9	1
3	Germline variation in the insulin-like growth factor pathway and risk of Barrettâ€™s esophagus and esophageal adenocarcinoma. Carcinogenesis, 2021, 42, 369-377.	2.8	11
4	Circulating MicroRNAs in Relation to Esophageal Adenocarcinoma Diagnosis and Survival. Digestive Diseases and Sciences, 2021, 66, 3831-3841.	2.3	3
5	Modeling historic incidence trends implies early field cancerization in esophageal squamous cell carcinoma. PLoS Computational Biology, 2021, 17, e1008961.	3.2	2
6	Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrettâ€™s Esophagus. Clinical Gastroenterology and Hepatology, 2020, 18, 2701-2709.e3.	4.4	12
7	Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration. British Journal of Cancer, 2020, 123, 1456-1463.	6.4	65
8	Sex-Specific Genetic Associations for Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. Gastroenterology, 2020, 159, 2065-2076.e1.	1.3	16
9	Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 427-433.	2.5	7
10	Lorenz Curves and Gini Coefficient Analyses Indicate Inefficiencies in Esophageal Adenocarcinoma Screening. Clinical Gastroenterology and Hepatology, 2019, 17, 560-562.e2.	4.4	5
11	Interactive decision support for esophageal adenocarcinoma screening and surveillance. BMC Gastroenterology, 2019, 19, 109.	2.0	4
12	Diabetes in relation to Barrettâ€™s esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrettâ€™s and Esophageal Adenocarcinoma Consortium. Cancer, 2019, 125, 4210-4223.	4.1	13
13	Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer: A bivariate spline model approach. Oral Oncology, 2019, 94, 47-57.	1.5	32
14	No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. Clinical Gastroenterology and Hepatology, 2019, 17, 2227-2235.e1.	4.4	16
15	Determining Risk of Barrettâ€™s Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and GeneticÂVariants. Gastroenterology, 2018, 154, 1273-1281.e3.	1.3	67
16	NSAID use and somatic exomic mutations in Barrettâ€™s esophagus. Genome Medicine, 2018, 10, 17.	8.2	16
17	Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrettâ€™s Esophagus. Clinical Gastroenterology and Hepatology, 2018, 16, 1598-1606.e4.	4.4	16
18	Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations. Communications Biology, 2018, 1, 174.	4.4	6

#	Article	IF	Citations
19	Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. American Journal of Gastroenterology, 2018, 113, 1148-1155.	0.4	57
20	External Validation of the Michigan Barrettâ€™s Esophagus Prediction Tool. Clinical Gastroenterology and Hepatology, 2017, 15, 1124-1126.	4.4	19
21	Quantification of familial risk of nasopharyngeal carcinoma in a highâ€incidence area. Cancer, 2017, 123, 2716-2725.	4.1	54
22	Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrettâ€™s esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics, 2017, 13, 1.	3.0	26
23	Active and Passive Smoking and Risk of Nasopharyngeal Carcinoma: A Population-Based Case-Control Study in Southern China. American Journal of Epidemiology, 2017, 185, 1272-1280.	3.4	68
24	Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. Gut, 2017, 66, 1739-1747.	12.1	38
25	A pooled analysis of dietary sugar/carbohydrate intake and esophageal and gastric cardia adenocarcinoma incidence and survival in the USA. International Journal of Epidemiology, 2017, 46, 1836-1846.	1.9	23
26	The Evolving Genomic Landscape of Barrettâ€™s Esophagus and Esophageal Adenocarcinoma. Gastroenterology, 2017, 153, 657-673.e1.	1.3	69
27	Evidence against a role for jaagsiekte sheep retrovirus in human lung cancer. Retrovirology, 2017, 14, 3.	2.0	9
28	Development of a population-based cancer case-control study in southern china. Oncotarget, 2017, 8, 87073-87085.	1.8	29
29	Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. International Journal of Cancer, 2016, 138, 1146-1152.	5.1	10
30	Oral Hygiene and Risk of Nasopharyngeal Carcinomaâ€”A Population-Based Caseâ€“Control Study in China. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1201-1207.	2.5	46
31	Constrained Score Statistics Identify Genetic Variants Interacting with Multiple Risk Factors in Barrettâ€™s Esophagus. American Journal of Human Genetics, 2016, 99, 352-365.	6.2	7
32	Leukocyte telomere length in relation to the risk of Barrett's esophagus and esophageal adenocarcinoma. Cancer Medicine, 2016, 5, 2657-2665.	2.8	6
33	Age-specific risk factor profiles of adenocarcinomas of the esophagus: A pooled analysis from the international BEACON consortium. International Journal of Cancer, 2016, 138, 55-64.	5.1	31
34	Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrettâ€™s Esophagus. American Journal of Gastroenterology, 2016, 111, 1528-1535.	0.4	28
35	Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. Lancet Oncology, The, 2016, 17, 1363-1373.	10.7	133
36	Inverse Association Between Gluteofemoral Obesity and Risk ofÂBarrettâ€™s Esophagus in a Pooled Analysis. Clinical Gastroenterology and Hepatology, 2016, 14, 1412-1419.e3.	4.4	12

#	Article	IF	Citations
37	Chronic gastroesophageal reflux disease shares genetic background with esophageal adenocarcinoma and Barrett's esophagus. Human Molecular Genetics, 2016, 25, 828-835.	2.9	31
38	Supportive evidence for <scp>FOXP</scp>1,<scp>BARX</scp>1, and <scp>FOXF</scp>1 as genetic risk loci for the development of esophageal adenocarcinoma. Cancer Medicine, 2015, 4, 1700-1704.	2.8	26
39	Obesity and inflammation markers in relation to leukocyte telomere length in a cross-sectional study of persons with Barrettâ€™s esophagus. BMC Obesity, 2015, 2, 32.	3.1	18
40	MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrettâ€™s Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium. PLoS ONE, 2015, 10, e0128617.	2.5	21
41	Bacterial Composition of the Human Upper Gastrointestinal Tract Microbiome Is Dynamic and Associated with Genomic Instability in a Barrettâ€™s Esophagus Cohort. PLoS ONE, 2015, 10, e0129055.	2.5	107
42	Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrettâ€™s Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium. PLoS ONE, 2015, 10, e0138738.	2.5	9
43	The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1012-1023.	2.5	35
44	A Newly Identified Susceptibility Locus nearFOXP1Modifies the Association of Gastroesophageal Reflux with Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1739-1747.	2.5	24
45	Dietary flavonoid intake and Barrett's esophagus in western Washington State. Annals of Epidemiology, 2015, 25, 730-735.e2.	1.9	6
46	Precision prevention of oesophageal adenocarcinoma. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 243-248.	17.8	129
47	Pleiotropic Analysis of Cancer Risk Loci on Esophageal Adenocarcinoma Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1801-1803.	2.5	7
48	Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus. Cancer Prevention Research, 2015, 8, 845-856.	1.5	44
49	A multinational assessment of gastric and esophageal cancer burden by age, gender, and disease characteristics.. Journal of Clinical Oncology, 2015, 33, 29-29.	1.6	0
50	Most common â€˜sporadicâ€™ cancers have a significant germline genetic component. Human Molecular Genetics, 2014, 23, 6112-6118.	2.9	85
51	From genomics to diagnostics of esophageal adenocarcinoma. Nature Genetics, 2014, 46, 806-807.	21.4	8
52	Alcohol and the Risk of Barrett's Esophagus: A Pooled Analysis from the International BEACON Consortium. American Journal of Gastroenterology, 2014, 109, 1586-1594.	0.4	55
53	Obesity and Risk of Esophageal Adenocarcinoma and Barrettâ€™s Esophagus: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2014, 106, .	6.3	132
54	Inflammation and Oxidative Stress Markers and Esophageal Adenocarcinoma Incidence in a Barrett's Esophagus Cohort. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2393-2403.	2.5	35

#	Article	IF	Citations
55	Diet and lifestyle factors and risk of subtypes of esophageal and gastric cancers: classification tree analysis. Annals of Epidemiology, 2014, 24, 50-57.	1.9	50
56	Risk of Esophageal Adenocarcinoma Decreases With Height, Based on Consortium Analysis and Confirmed by Mendelian Randomization. Clinical Gastroenterology and Hepatology, 2014, 12, 1667-1676.e1.	4.4	30
57	Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis, 2014, 35, 2740-2747.	2.8	31
58	Gastroesophageal Reflux in Relation to Adenocarcinomas of the Esophagus: A Pooled Analysis from the Barrettâ€™s and Esophageal Adenocarcinoma Consortium (BEACON). PLoS ONE, 2014, 9, e103508.	2.5	134
59	Genomic determinants of prognosis in esophageal adenocarcinoma: Using computational methods to account for gene-gene interactions.. Journal of Clinical Oncology, 2014, 32, 42-42.	1.6	0
60	Germline Genetic Contributions to Risk for Esophageal Adenocarcinoma, Barrett's Esophagus, and Gastroesophageal Reflux. Journal of the National Cancer Institute, 2013, 105, 1711-1718.	6.3	85
61	A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nature Genetics, 2013, 45, 1487-1493.	21.4	174
62	Sex-specific associations between body mass index, waist circumference and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. Gut, 2013, 62, 1684-1691.	12.1	118
63	The Role of Tobacco, Alcohol, and Obesity in Neoplastic Progression to Esophageal Adenocarcinoma: A Prospective Study of Barrett's Esophagus. PLoS ONE, 2013, 8, e52192.	2.5	80
64	Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. International Journal of Epidemiology, 2012, 41, 1706-1718.	1.9	237
65	Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nature Genetics, 2012, 44, 1131-1136.	21.4	162
66	Use of Statin Medications and Risk of Esophageal Adenocarcinoma in Persons with Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 456-461.	2.5	45
67	A Clinical Risk Prediction Model for Barrett Esophagus. Cancer Prevention Research, 2012, 5, 1115-1123.	1.5	67
68	Nonsteroidal Anti-inflammatory Drug Use Reduces Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction in a Pooled Analysis. Gastroenterology, 2012, 142, 442-452.e5.	1.3	140
69	Hormonal Factors and Risks of Esophageal Squamous Cell Carcinoma and Adenocarcinoma in Postmenopausal Women. Cancer Prevention Research, 2011, 4, 840-850.	1.5	50
70	Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nature Reviews Cancer, 2010, 10, 87-101.	28.4	346
71	Cigarette Smoking and Adenocarcinomas of the Esophagus and Esophagogastric Junction: A Pooled Analysis From the International BEACON Consortium. Journal of the National Cancer Institute, 2010, 102, 1344-1353.	6.3	259
72	NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma. PLoS Medicine, 2007, 4, e67.	8.4	228

#	Article	IF	Citations
73	Central Adiposity and Risk of Barrettâ€™s Esophagus. Gastroenterology, 2007, 133, 403-411.	1.3	276
74	Gastrointestinal Cancers. , 2006, , 239-252.		0
75	Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncology, The, 2005, 6, 945-952.	10.7	196
76	Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clinical Gastroenterology and Hepatology, 2005, 3, 225-230.	4.4	74
77	Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 745-52.	2.5	40
78	Family history of cancer and risk of esophageal and gastric cancers in the United States. International Journal of Cancer, 2001, 93, 148-152.	5.1	127
79	Exposures to wood dust in U.S. industries and occupations, 1979 to 1997. , 1999, 35, 581-589.		48
80	Diet and nasopharyngeal cancer in a low-risk population. , 1998, 78, 675-679.		68
81	Neurophysiological Function in Farm Workers Exposed to Organophosphate Pesticides. Archives of Environmental Health, 1998, 53, 7-14.	0.4	43
82	Fluid intake and the incidence of bladder cancer among middleâ€aged men and women in a threeâ€county area of western Washington. Nutrition and Cancer, 1997, 29, 163-168.	2.0	75
83	Cancer incidence among alachlor manufacturing workers. , 1996, 30, 300-306.		40
84	A protective association between the HLA-A2 antigen and nasopharyngeal carcinoma in us caucasians. International Journal of Cancer, 1994, 56, 465-467.	5.1	46
85	A case-control study of multiple myeloma and occupation. American Journal of Industrial Medicine, 1993, 23, 629-639.	2.1	77
86	Descriptive epidemiology and survival analysis of nasopharyngeal carcinoma in the united states. International Journal of Cancer, 1992, 52, 549-556.	5.1	75
87	A case-control study of oral cancer and pre-diagnostic concentrations of selenium and zinc in nail tissue. International Journal of Cancer, 1991, 48, 182-188.	5.1	41
88	A caseâ€control study of maternal smoking and congenital malformations. Paediatric and Perinatal Epidemiology, 1990, 4, 147-155.	1.7	87
89	Diet and pharyngeal cancer. International Journal of Cancer, 1989, 44, 593-597.	5.1	74
90	Occupation and squamous cell cancers of the pharynx and sinonasal cavity. American Journal of Industrial Medicine, 1989, 16, 493-510.	2.1	36

#	Article	IF	Citations
91	B cell neoplasms and occupational asbestos exposure. American Journal of Industrial Medicine, 1988, 14, 661-671.	2.1	26
92	Formaldehyde and cancers of the pharynx, sinus and nasal cavity: I. Occupational exposures. International Journal of Cancer, 1986, 38, 677-683.	5.1	96
93	Formaldehyde and cancers of the pharynx, sinus and nasal cavity: II. Residential exposures. International Journal of Cancer, 1986, 38, 685-688.	5.1	84
94	eQTL set-based association analysis identifies novel susceptibility loci for Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 0, , .	2.5	1